Target

MEK

Mitogen-activated protein kinase kinase

Also: MEK1, MEK2

29open trials
81trials in total
215publications
0researchers

Diseases

The last 24 months

New trials, publications, preprints and grants on this target, month by month.

TrialsPublicationsPreprintsGrants

Trial
Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy: Baby MERIT
1 Aug 2027· PHASE3 · NOT_YET_RECRUITING· CTGOV
Trial
Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma
1 Jun 2027· PHASE1_PHASE2 · RECRUITING· CTGOV
Trial
Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults
4 Jan 2027· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Selumetinib for NF2-Related Schwannomatosis
1 Dec 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Post-transplant BRAF/MEK inhibitor maintenance sustains complete remission in BRAF V600E-mutant histiocytic sarcoma.
28 Oct 2026· Annals of hematology· PUBMED
Publication
Treatment discontinuation after complete response to BRAF/MEK inhibition in metastatic melanoma: long-term clinical outcomes from a single institution.
28 Oct 2026· Melanoma research· PUBMED
Publication
Targeted BRAF /MEK inhibition as a salvage therapy for patients with metastatic melanoma harboring a BRAF L597R mutation: two case reports and review of the literature.
28 Oct 2026· Melanoma research· PUBMED
Publication
TFAP2A-driven PTK6 promotes endometrial cancer progression through activation of the MEK/ERK signaling pathway.
26 Oct 2026· International immunopharmacology· PUBMED
Publication
MEK inhibitors in NF1-associated high-grade glioma: partial responses and outcomes from a single-institution cohort and literature review.
22 Oct 2026· Journal of neuro-oncology· PUBMED
Publication
[Patients with papillary craniopharyngioma successfully treated with BRAF and MEK inhibitors].
16 Oct 2026· Lakartidningen· PUBMED
Publication
Inhibition of the MEK-ERK signaling pathway reverses acquired osimertinib resistance in NSCLC attributed to AXL overexpression.
13 Oct 2026· Life sciences· PUBMED
Publication
Dual inhibition of JAK and MEK suppresses T-cell acute lymphoblastic leukemia induced by mutant IL7R and RASGRP1 overexpression.
8 Oct 2026· Haematologica· PUBMED
Publication
Efficacy and safety of MEK inhibitors for NF1-associated symptomatic, inoperable plexiform neurofibromas: A systematic review and meta-analysis.
6 Oct 2026· PloS one· PUBMED
Publication
Tomatidine hydrochloride suppresses intrahepatic cholangiocarcinoma progression by modulating CPA4 and inhibiting the MEK/ERK signaling pathway.
4 Oct 2026· Tissue & cell· PUBMED
Trial
Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma
1 Oct 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Erratum: Additive effect of Ruta graveolens bioactive phytoconstituents and cisplatin through PKC/MEK/ERK pathway in glioblastoma.
1 Oct 2026· Molecular therapy. Oncology· PUBMED
Publication
FAK inhibitor and RAF/MEK clamp avutometinib enhance KRAS G12C inhibitor efficacy in preclinical models of non-small cell lung cancer.
30 Sept 2026· Science translational medicine· PUBMED
Publication
G Protein-Coupled Receptor 68 Promotes the Progression of Triple-Negative Breast Cancer and Cuproptosis Resistance via the MEK/ERK Signaling Pathway.
30 Sept 2026· FASEB journal : official publication of the Federation of American Societies for Experimental Biology· PUBMED
Publication
Targeting the untargeted: Emerging targeted therapies in metastatic melanoma beyond BRAF/MEK inhibitors.
28 Sept 2026· Critical reviews in oncology/hematology· PUBMED
Publication
Multilayer human data prioritise RAF-MEK-ERK/MAPK3 as a candidate signalling axis of depressive disorder relevance within the target landscape of Gegen Qinlian Decoction.
23 Sept 2026· Computational biology and chemistry· PUBMED
Publication
SNU523 Inhibits Pancreatic Cancer through the Dual Suppression of STAT3 and MEK Signaling Pathways.
21 Sept 2026· ACS omega· PUBMED
Publication
Ligand-based pharmacophore modeling and molecular dynamics driven discovery of novel MEK1 inhibitors targeting KRAS signalling pathway.
21 Sept 2026· Journal of molecular graphics & modelling· PUBMED
Publication
Deoxycalyxin A exerts hypoglycemic effects through activating TGR5-induced GLP-1 secretion via TGR5/PKA/MEK/ERK pathway.
14 Sept 2026· Bioorganic chemistry· PUBMED
Publication
RAF/MEK clamp inhibition with avutometinib and cetuximab in RAF1 S257L-mutated, anti-EGFR-refractory metastatic colorectal cancer in Gaucher's disease.
9 Sept 2026· The oncologist· PUBMED
Publication
MEK inhibitor-based genomically matched combinatorial targeted therapies in metastatic pancreatic adenocarcinoma with KRAS alterations.
9 Sept 2026· The oncologist· PUBMED
Publication
SRPK Inhibition in Cholangiocarcinoma Cells Induces LAMB1-Associated Adaptive Responses and Enhances Growth Suppression by the MEK Inhibitor U0126 via the LAMB1/ERK/c-JUN Axis.
7 Sept 2026· Frontiers in bioscience (Landmark edition)· PUBMED
Publication
Paeoniflorin attenuates experimental autoimmune encephalomyelitis in mice in association with enhanced Treg differentiation and activation of Raf/MEK1/2/ERK1/2/Egr-1 signaling.
3 Sept 2026· Naunyn-Schmiedeberg's archives of pharmacology· PUBMED
Publication
Exploring the Role of TERT Promoter Mutations in Advanced Melanoma Treated With BRAF/MEK Inhibitors or Immune Checkpoint Inhibitors.
1 Sept 2026· Anticancer research· PUBMED
Publication
Are Metabolic Imaging Biomarkers Ready for Clinical Translation in BRAF/MEK-Targeted Melanoma Therapy?
31 Aug 2026· Academic radiology· PUBMED
Publication
Comparison of the Effects of Sorafenib and Stem Cell Secretome on HepG2 Cancer Cells with Respect to the Ras/Raf/MEK/ERK Pathway.
30 Aug 2026· Journal of clinical medicine· PUBMED

Who works on it

Researchers who published on this target. Leave out your own co-author circle to find people you do not know yet.

No published researcher profile on this target yet.

We look for a fixed list of target names in titles, keywords, intervention names and MeSH terms. A mention does not prove that the work is aimed at that target.

Report an error